(Q38137006)

29 August 2017

title

13-valent pneumococcal conjugate vaccine: a review of its use in infants, children, and adolescents (English)

1 reference

pneumococcal conjugate vaccine

29 August 2017

1 reference

1 reference

1

Greg L Plosker

1 reference

29 August 2017

publication date

1 October 2013

1 reference

29 August 2017

1 reference

29 August 2017

volume

15

1 reference

29 August 2017

issue

5

1 reference

29 August 2017

page(s)

403-423

1 reference

https://scigraph.springernature.com/pub.10.1007/s40272-013-0047-z

29 August 2017

exact match

0 references

cites work

Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0047-Z

Pneumococcal vaccines for children: a global public health priority.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0047-Z

The burden of pneumonia in children in the developed world

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0047-Z

The worldwide impact of the seven-valent pneumococcal conjugate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0047-Z

Modeling the decline in pneumococcal acute otitis media following the introduction of pneumococcal conjugate vaccines in the US.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0047-Z

Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate Vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0047-Z

Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0047-Z

Serotype 19A Is the most common serotype causing invasive pneumococcal infections in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0047-Z

Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0047-Z

Prevention of pneumococcal diseases in the post-seven valent vaccine era: a European perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0047-Z

Summary of invasive pneumococcal disease burden among children in the Asia-Pacific region

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0047-Z

Effect of pneumococcal conjugate vaccine on pneumococcal meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0047-Z

Pneumococcal disease caused by serotype 19A: review of the literature and implications for future vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0047-Z

Increase in serotype 19A prevalence and amoxicillin non-susceptibility among paediatric Streptococcus pneumoniae isolates from middle ear fluid in a passive laboratory-based surveillance in Spain, 1997-2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0047-Z

Pneumococcal carriage and antibiotic resistance in young children before 13-valent conjugate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0047-Z

Pneumococcal carriage and invasive disease in children before introduction of the 13-valent conjugate vaccine: comparison with the era before 7-valent conjugate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0047-Z

Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) [prevenar 13®].

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0047-Z

A phase 3, randomized, double-blind trial comparing the safety and immunogenicity of the 7-valent and 13-valent pneumococcal conjugate vaccines, given with routine pediatric vaccinations, in healthy infants in Brazil

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0047-Z

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine given with routine pediatric vaccines in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0047-Z

Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0047-Z

Challenges in the evaluation and licensing of new pneumococcal vaccines, 7-8 July 2008, Ottawa, Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0047-Z

The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0047-Z

Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0047-Z

Immunogenicity and reactogenicity of a 13-valent-pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: a double-blind randomized active-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0047-Z

Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in children previously immunized with 7-valent pneumococcal conjugate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0047-Z

13-Valent pneumococcal conjugate vaccine (PCV13) in children partially immunized with 7-valent pneumococcal conjugate vaccine (PCV7): a phase 3, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0047-Z

Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0047-Z

Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0047-Z

Pneumococcal serotypes before and after introduction of conjugate vaccines, United States, 1999-2011(1.).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0047-Z

PCV13 impact evaluations: the obvious and the unpredicted

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0047-Z

Mathematical modelling long-term effects of replacing Prevnar7 with Prevnar13 on invasive pneumococcal diseases in England and Wales

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0047-Z

Modeling the impact of the 13-valent pneumococcal conjugate vaccine serotype catch-up program using United States claims data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0047-Z

Forecasting invasive pneumococcal disease trends after the introduction of 13-valent pneumococcal conjugate vaccine in the United States, 2010-2020.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0047-Z

Postlicensure surveillance for pre-specified adverse events following the 13-valent pneumococcal conjugate vaccine in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0047-Z

The cost-effectiveness of a 13-valent pneumococcal conjugate vaccination for infants in England

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0047-Z

Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0047-Z

Pharmacoeconomic assessment of implementing a universal PCV-13 vaccination programme in the Valencian public health system (Spain).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0047-Z

Economic and clinical evaluation of a catch-up dose of 13-valent pneumococcal conjugate vaccine in children already immunized with three doses of the 7-valent vaccine in Italy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0047-Z

Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0047-Z

Cost-effectiveness of new pneumococcal conjugate vaccines in Turkey: a decision analytical model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0047-Z

Economic evaluation of vaccination programme of 13-valent pneumococcal conjugate vaccine to the birth cohort in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0047-Z

Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0047-Z

Cost-effectiveness of pneumococcal conjugate vaccines of 7, 10, and 13 valences in Colombian children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0047-Z

Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0047-Z

Cost-utility analysis of 10- and 13-valent pneumococcal conjugate vaccines: protection at what price in the Thai context?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0047-Z

Effect of vaccination with pneumococcal capsular polysaccharides conjugated to Haemophilus influenzae-derived protein D on nasopharyngeal carriage of Streptococcus pneumoniae and H. influenzae in children under 2 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0047-Z

Effects of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D-conjugate vaccine on nasopharyngeal bacterial colonization in young children: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0047-Z

The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0047-Z

Recommendations for the prevention of Streptococcus pneumoniae infections in infants and children: use of 13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0047-Z

Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0047-Z

Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0047-Z

Safety and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers Given With Routine Pediatric Vaccinations in Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0047-Z

Cost-effectiveness analysis of pneumococcal conjugate vaccine in Taiwan: a transmission dynamic modeling approach

21 January 2018

1 reference

12 December 2020

Cost-effectiveness of using 2 vs 3 primary doses of 13-valent pneumococcal conjugate vaccine

1 reference

12 December 2020

Update on the success of the pneumococcal conjugate vaccine

1 reference

12 December 2020

Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given to korean children receiving routine pediatric vaccines

1 reference

12 December 2020

The 13-valent pneumococcal conjugate vaccine for invasive pneumococcal disease in Alaska native children: results of a clinical trial

1 reference

12 December 2020

Economic evaluation of second generation pneumococcal conjugate vaccines in Norway

1 reference

12 December 2020

Pharmacoeconomic evaluation of 10- and 13-valent pneumococcal conjugate vaccines

1 reference

12 December 2020

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine (PCV13) when given as a toddler dose to children immunized with PCV7 as infants

1 reference

12 December 2020

Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine

1 reference

12 December 2020

Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study

1 reference

12 December 2020

Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers

1 reference

12 December 2020

Rapid reduction in invasive pneumococcal disease after introduction of PCV7 into the National Immunization Plan in Israel

1 reference

12 December 2020

13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study

1 reference

12 December 2020

13-valent pneumococcal conjugate vaccine given with meningococcal C-tetanus toxoid conjugate and other routine pediatric vaccinations: immunogenicity and safety

1 reference

12 December 2020

The potential cost-effectiveness of infant pneumococcal vaccines in Australia

1 reference

12 December 2020

Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children - Advisory Committee on Immunization Practices (ACIP), 2010

1 reference

12 December 2020

Cost-effectiveness of 13-valent pneumococcal conjugate vaccine in Switzerland

1 reference

12 December 2020

Streptococcus pneumoniae: epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines

1 reference

12 December 2020

Impact of the 10-valent pneumococcal non-typeable Haemophilus influenzae Protein D conjugate vaccine (PHiD-CV) on bacterial nasopharyngeal carriage

1 reference

12 December 2020

Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media.

1 reference

12 December 2020

Pneumococcal disease in South Australia: vaccine success but no time for complacency

1 reference

12 December 2020

Invasive pneumococcal disease in young children before licensure of 13-valent pneumococcal conjugate vaccine - United States, 2007.

1 reference

12 December 2020

Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States

1 reference

12 December 2020

Cost-effectiveness analysis of the 10- and 13-valent pneumococcal conjugate vaccines in Argentina

1 reference

12 December 2020

Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany

1 reference

12 December 2020

Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The Netherlands

1 reference

12 December 2020

Comparing health outcomes and costs of general vaccination with pneumococcal conjugate vaccines in Sweden: a Markov model

1 reference

12 December 2020

10.1007/S40272-013-0047-Z

Identifiers

DOI

1 reference

Dimensions Publication ID

29 August 2017

1010091024

0 references

1 reference